Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial

BACKGROUND: Preoperative and perioperative aromatase inhibitor (POAI) therapy has the potential to improve outcomes in women with operable oestrogen receptor-positive primary breast cancer. It has also been suggested that tumour Ki67 values after 2 weeks (Ki67(2W)) of POAI predicts individual patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Ian, Robertson, John, Kilburn, Lucy, Wilcox, Maggie, Evans, Abigail, Holcombe, Chris, Horgan, Kieran, Kirwan, Cliona, Mallon, Elizabeth, Sibbering, Mark, Skene, Anthony, Vidya, Raghavan, Cheang, Maggie, Banerji, Jane, Morden, James, Sidhu, Kally, Dodson, Andrew, Bliss, Judith M, Dowsett, Mitch
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606901/
https://www.ncbi.nlm.nih.gov/pubmed/33152284
http://dx.doi.org/10.1016/S1470-2045(20)30458-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606901/
https://www.ncbi.nlm.nih.gov/pubmed/33152284
http://dx.doi.org/10.1016/S1470-2045(20)30458-7

Ejemplares similares